keyword
MENU ▼
Read by QxMD icon Read
search

Jan burger

keyword
https://www.readbyqxmd.com/read/28284741/long-term-environmental-radioactive-contamination-of-europe-due-to-the-chernobyl-accident-results-of-the-joint-danube-survey-2013
#1
Franz Josef Maringer, Claudia Ackerl, Andreas Baumgartner, Christopher Burger-Scheidlin, Maria Kocadag, Johannes H Sterba, Michael Stietka, Jan Matthew Welch
In the course of the Joint Danube Survey 3 (JDS3), coordinated by the International Commission for the Protection of the Danube River (ICPDR), laboratory ships travelled 2375km down the Danube River engaging in sampling, processing and on-board analyses during the summer of 2013. The results of the radiometric analysis of (90)Sr, (137)Cs and natural radionuclides in recent riverbed sediment are presented. The activity concentrations of (90)Sr and (137)Cs in Danube sediments have been found below 100Bq/kg.
February 27, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28266239/guideline-on-the-diagnosis-and-treatment-of-primary-idiopathic-clubfoot
#2
Arnold T Besselaar, Ralph J B Sakkers, Hans A Schuppers, Melinda M E H Witbreuk, Elgun V C M Zeegers, Jan D Visser, Robert A Boekestijn, Sacha D Margés, M C Marieke Van der Steen, Koert N J Burger
- A delegation of 6 pediatric orthopedic surgeons from the Dutch Orthopedic Association (NOV) and 2 members of the board of the Dutch Parents' Association for children with clubfoot created the guideline "The diagnosis and treatment of primary idiopathic clubfeet" between April 2011 and February 2014. The development of the guideline was supported by a professional methodologist from the Dutch Knowledge Institute of Medical Specialists. This evidence-based guideline process was new and unique, in the sense that the process was initiated by a parents' association...
March 7, 2017: Acta Orthopaedica
https://www.readbyqxmd.com/read/28171709/long-term-outcomes-for-patients-with-chronic-lymphocytic-leukemia-who-discontinue-ibrutinib
#3
Preetesh Jain, Philip A Thompson, Michael Keating, Zeev Estrov, Alessandra Ferrajoli, Nitin Jain, Hagop Kantarjian, Jan A Burger, Susan O'Brien, William G Wierda
BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor and is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) in frontline and relapsed/refractory settings. The authors previously reported poor outcomes for patients who discontinued ibrutinib; however, long-term outcomes were not reported. METHODS: Data from 320 patients who received ibrutinib on clinical studies between 2010 and 2015 at The University of Texas MD Anderson Cancer Center were retrospectively analyzed...
February 7, 2017: Cancer
https://www.readbyqxmd.com/read/28153836/hsp90-a-chaperone-that-can-make-you-syk
#4
Elisa Ten Hacken, Jan A Burger
No abstract text is available yet for this article.
February 2, 2017: Blood
https://www.readbyqxmd.com/read/28138560/leukemia-cell-proliferation-and-death-in-chronic-lymphocytic-leukemia-patients-on-therapy-with-the-btk-inhibitor-ibrutinib
#5
Jan A Burger, Kelvin W Li, Michael J Keating, Mariela Sivina, Ahmed M Amer, Naveen Garg, Alessandra Ferrajoli, Xuelin Huang, Hagop Kantarjian, William G Wierda, Susan O'Brien, Marc K Hellerstein, Scott M Turner, Claire L Emson, Shih-Shih Chen, Xiao-Jie Yan, Dominik Wodarz, Nicholas Chiorazzi
BACKGROUND. Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) that inhibits Bruton's tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. METHODS. We used stable isotopic labeling with deuterated water ((2)H2O) to measure directly the effects of ibrutinib on leukemia cell proliferation and death in 30 patients with CLL. RESULTS. The measured average CLL cell proliferation ("birth") rate before ibrutinib therapy was 0.39% of the clone per day (range 0...
January 26, 2017: JCI Insight
https://www.readbyqxmd.com/read/28130399/constitutive-phosphorylation-of-stat3-by-the-ck2-blnk-cd5-complex
#6
Uri Rozovski, David M Harris, Ping Li, Zhiming Liu, Preetesh Jain, Ivo Veletic, Alessandra Ferrajoli, Jan Burger, Susan O'Brien, Prithviraj Bose, Philip Thompson, Nitin Jain, William Wierda, Michael J Keating, Zeev Estrov
In chronic lymphocytic leukemia (CLL), STAT3 is constitutively phosphorylated on serine 727 and plays a role in the pathobiology of CLL. However, what induces constitutive phosphorylation of STAT3 is currently unknown. Mass spectrometry was used to identify casein kinase 2 (CK2), a serine/threonine kinase that co-immunoprecipitated with serine phosphorylated STAT3 (pSTAT3). Furthermore, activated CK2 incubated with recombinant STAT3 induced phosphorylation of STAT3 on serine 727. Although STAT3 and CK2 are present in normal B- and T-cells, STAT3 is not constitutively phosphorylated in these cells...
January 27, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28113628/a-multiple-label-guided-clustering-algorithm-for-historical-document-dating-and-localization
#7
Sheng He, Petros Samara, Jan Burgers, Lambert Schomaker
It is of essential importance for historians to know the date and place of origin of the documents they study. It would be a huge advancement for historical scholars if it would be possible to automatically estimate the geographical and temporal provenance of a handwritten document by inferring them from the handwriting style of such a document. We propose a multiple-label guided clustering algorithm to discover the correlations between the concrete low-level visual elements in historical documents and abstract labels, such as date and location...
August 24, 2016: IEEE Transactions on Image Processing: a Publication of the IEEE Signal Processing Society
https://www.readbyqxmd.com/read/28089238/ruxolitinib-for-symptom-control-in-patients-with-chronic-lymphocytic-leukaemia-a-single-group-phase-2-trial
#8
Preetesh Jain, Michael Keating, Sarah Renner, Charles Cleeland, Huang Xuelin, Graciela Nogueras Gonzalez, David Harris, Ping Li, Zhiming Liu, Ivo Veletic, Uri Rozovski, Nitin Jain, Phillip Thompson, Prithviraj Bose, Courtney DiNardo, Alessandra Ferrajoli, Susan O'Brien, Jan Burger, William Wierda, Srdan Verstovsek, Hagop Kantarjian, Zeev Estrov
BACKGROUND: Disease-related symptoms impair the quality of life of patients with chronic lymphocytic leukaemia (CLL) who do not require systemic therapy. Available therapies are not specifically aimed at symptom control. Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2 inhibitor ruxolitinib improves symptoms in patients with myelofibrosis, we postulated that ruxolitinib would improve disease-related symptoms in patients with CLL. We did a phase 2 trial of ruxolitinib to test this hypothesis...
February 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28077600/ibrutinib-therapy-increases-t-cell-repertoire-diversity-in-patients-with-chronic-lymphocytic-leukemia
#9
Qingsong Yin, Mariela Sivina, Harlan Robins, Erik Yusko, Marissa Vignali, Susan O'Brien, Michael J Keating, Alessandra Ferrajoli, Zeev Estrov, Nitin Jain, William G Wierda, Jan A Burger
The Bruton's tyrosine kinase inhibitor ibrutinib is a highly effective, new targeted therapy for chronic lymphocytic leukemia (CLL) that thwarts leukemia cell survival, growth, and tissue homing. The effects of ibrutinib treatment on the T cell compartment, which is clonally expanded and thought to support the growth of malignant B cells in CLL, are not fully characterized. Using next-generation sequencing technology, we characterized the diversity of TCRβ-chains in peripheral blood T cells from 15 CLL patients before and after 1 y of ibrutinib therapy...
February 15, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28073846/extended-treatment-with-single-agent-ibrutinib-at-the-420-mg-dose-leads-to-durable-responses-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma
#10
Steven E Coutré, Richard R Furman, Ian W Flinn, Jan A Burger, Kristie Blum, Jeff Sharman, Jeffrey Jones, William Wierda, Weiqiang Zhao, Nyla A Heerema, Amy J Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F James, John C Byrd, Susan O'Brien
Purpose: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve (TN) or had relapsed/refractory (R/R) CLL after ≥1 prior therapy in a phase Ib/II study (PCYC-1102). Subsequently, the ibrutinib 420 mg dose was approved in CLL...
January 10, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28031181/ibrutinib-inhibits-pre-bcr-b-cell-acute-lymphoblastic-leukemia-progression-by-targeting-btk-and-blk
#11
Ekaterina Kim, Christian Hurtz, Stefan Koehrer, Zhiqiang Wang, Sriram Balasubramanian, Betty Y Chang, Markus Müschen, R Eric Davis, Jan A Burger
Targeting B-cell receptor (BCR) signaling is a successful therapeutic strategy in mature B-cell malignancies. Precursor BCR (pre-BCR) signaling, which is critical during normal B lymphopoiesis, also plays an important role in pre-BCR(+) B cell acute lymphoblastic leukemia (B-ALL). Here, we investigated the activity and mechanism of action of the BTK inhibitor ibrutinib in preclinical models of B-ALL. Pre-BCR(+) ALL cells were exquisitely sensitive to ibrutinib at therapeutically relevant drug concentrations...
March 2, 2017: Blood
https://www.readbyqxmd.com/read/27924711/occupational-risk-factors-for-relapse-free-survival-in-bladder-cancer-patients
#12
Silvia Selinski, Hannah Bürger, Meinolf Blaszkewicz, Thomas Otto, Frank Volkert, Oliver Moormann, Hartmut Niedner, Jan G Hengstler, Klaus Golka
The influence of occupational risk factors on bladder cancer development is well investigated. However, studies on the influence on bladder cancer prognosis are rare. Therefore, it was of interest to investigate the time to first relapse in the follow-ups of three case-control series from Dortmund, Neuss, and Lutherstadt Wittenberg, Germany. Relapse-free survival of in total 794 urinary bladder cancer patients (Dortmund 174, Neuss 407, Lutherstadt Wittenberg 213) was derived from medical records. Cox regression models were used to determine the impact of profession and exposure to bladder carcinogens if the risk factor was present in at least four cases...
2016: Journal of Toxicology and Environmental Health. Part A
https://www.readbyqxmd.com/read/27924709/occupational-risk-factors-for-prostate-cancer-in-an-area-of-former-coal-iron-and-steel-industries-in-germany-part-2-results-from-a-study-performed-in-the-1990s
#13
Sabina Krech, Silvia Selinski, Hannah Bürger, Jan G Hengstler, Peter Jedrusik, Jasmin Hodzic, H-Jürgen Knopf, Klaus Golka
Currently, there is no established occupational risk factor for prostate cancer. However, in the 1980s, a hospital-based case-control study in the greater Dortmund area showed an elevated risk for hard coal miners and, based on few cases, for painters and varnishers. Therefore, approximately 10 yr later, a similar study regarding prostate cancer was performed in this area. In total, 292 patients with prostate cancer who underwent radical prostatectomy and 313 controls who underwent transurethral resection of a benign prostatic hyperplasia were investigated by questionnaire...
2016: Journal of Toxicology and Environmental Health. Part A
https://www.readbyqxmd.com/read/27919243/tumour-stage-distribution-and-survival-of-malignant-melanoma-in-germany-2002-2011
#14
Olaf Schoffer, Stefanie Schülein, Gerlinde Arand, Hans Arnholdt, Dieter Baaske, Ralf C Bargou, Nikolaus Becker, Matthias W Beckmann, Yves Bodack, Beatrix Böhme, Tayfun Bozkurt, Regine Breitsprecher, Andre Buchali, Elke Burger, Ulrike Burger, Klaus Dommisch, Gudrun Elsner, Karin Fernschild, Ulrike Flintzer, Uwe Funke, Michael Gerken, Hubert Göbel, Norbert Grobe, Vera Gumpp, Lucie Heinzerling, Lana Raffaela Kempfer, Alexander Kiani, Monika Klinkhammer-Schalke, Sabine Klöcking, Ute Kreibich, Katrin Knabner, Peter Kuhn, Stine Lutze, Uwe Mäder, Tanja Maisel, Jan Maschke, Martin Middeke, Andreas Neubauer, Antje Niedostatek, Anabelle Opazo-Saez, Christoph Peters, Beatrice Schell, Gerhard Schenkirsch, Harald Schmalenberg, Peter Schmidt, Constanze Schneider, Birgit Schubotz, Anika Seide, Paul Strecker, Sabine Taubenheim, Matthias Wackes, Steffen Weiß, Claudia Welke, Carmen Werner, Christian Wittekind, Jörg Wulff, Heike Zettl, Stefanie J Klug
BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival...
December 5, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27897414/a-comparative-study-of-software-programmes-for-cross-sectional-skeletal-muscle-and-adipose-tissue-measurements-on-abdominal-computed-tomography-scans-of-rectal-cancer-patients
#15
Jeroen L A van Vugt, Stef Levolger, Arvind Gharbharan, Marcel Koek, Wiro J Niessen, Jacobus W A Burger, Sten P Willemsen, Ron W F de Bruin, Jan N M IJzermans
BACKGROUND: The association between body composition (e.g. sarcopenia or visceral obesity) and treatment outcomes, such as survival, using single-slice computed tomography (CT)-based measurements has recently been studied in various patient groups. These studies have been conducted with different software programmes, each with their specific characteristics, of which the inter-observer, intra-observer, and inter-software correlation are unknown. Therefore, a comparative study was performed...
November 22, 2016: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/27797975/long-term-follow-up-of-treatment-with-ibrutinib-and-rituximab-in-patients-with-high-risk-chronic-lymphocytic-leukemia
#16
Preetesh Jain, Michael J Keating, William G Wierda, Mariela Sivina, Philip A Thompson, Alessandra Ferrajoli, Zeev Estrov, Hagop Kantarjian, Susan O'Brien, Jan A Burger
Background: Ibrutinib is an active therapy with an acceptable safety profile for patients with chronic lymphocytic leukemia (CLL), including high-risk patients with del17p or with TP53 mutations. Ibrutinib is broadly indicated for the treatment of patients with CLL and specifically including those with 17p deletion. The optimal use of ibrutinib in combination with other agents remains controversial.Methods: We report the long-term outcome [median follow-up of 47 months (range, 36-51 months)] of 40 patients with high-risk CLL, treated on the first ibrutinib combination trial with rituximab (IR)...
October 19, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27786334/cd70-limits-atherosclerosis-and-promotes-macrophage-function
#17
Holger Winkels, Svenja Meiler, Esther Smeets, Dirk Lievens, David Engel, Charlotte Spitz, Christina Bürger, Petteri Rinne, Linda Beckers, Angelika Dandl, Sigrid Reim, Maiwand Ahmadsei, Jan Van den Bossche, Lesca M Holdt, Remco T A Megens, Martin Schmitt, Menno de Winther, Eric A Biessen, Jannie Borst, Alexander Faussner, Christian Weber, Esther Lutgens, Norbert Gerdes
The co-stimulatory molecule CD70 is expressed on activated immune cells and is known to modulate responses of T, B, and NK cells via its receptor CD27. Until now, there is only limited data describing the role of CD70 in atherosclerosis. We observed that ruptured human carotid atherosclerotic plaques displayed higher CD70 expression than stable carotid atherosclerotic plaques, and that CD70 expression in murine atheroma localized to macrophages. Lack of CD70 impaired the inflammatory capacity (e. g. reactive oxygen species and nitric oxide production) of bone marrow-derived macrophages, increased both M1-like and M2-like macrophage markers, and rendered macrophages metabolically inactive and prone to apoptosis...
October 27, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27765613/the-use-of-neoadjuvant-chemotherapy-in-patients-with-urothelial-carcinoma-of-the-bladder-current-practice-among-clinicians
#18
Thomas Martini, Christian Gilfrich, Roman Mayr, Maximilian Burger, Armin Pycha, Atiqullah Aziz, Michael Gierth, Christian G Stief, Stefan C Müller, Florian Wagenlehner, Jan Roigas, Oliver W Hakenberg, Florian Roghmann, Philipp Nuhn, Manfred Wirth, Vladimir Novotny, Boris Hadaschik, Marc-Oliver Grimm, Paul Schramek, Axel Haferkamp, Daniela Colleselli, Birgit Kloss, Edwin Herrmann, Margit Fisch, Matthias May, Christian Bolenz
INTRODUCTION: Guidelines recommend neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in patients with urothelial carcinoma of the bladder in clinical stages T2-T4a, cN0M0. We examined the frequency and current practice of NAC and sought to identify predictors for the use of NAC in a prospective contemporary cohort. MATERIALS AND METHODS: We analyzed prospective data from 679 patients in the PROMETRICS (PROspective MulticEnTer RadIcal Cystectomy Series 2011) database...
September 19, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27754477/early-cave-art-and-ancient-dna-record-the-origin-of-european-bison
#19
Julien Soubrier, Graham Gower, Kefei Chen, Stephen M Richards, Bastien Llamas, Kieren J Mitchell, Simon Y W Ho, Pavel Kosintsev, Michael S Y Lee, Gennady Baryshnikov, Ruth Bollongino, Pere Bover, Joachim Burger, David Chivall, Evelyne Crégut-Bonnoure, Jared E Decker, Vladimir B Doronichev, Katerina Douka, Damien A Fordham, Federica Fontana, Carole Fritz, Jan Glimmerveen, Liubov V Golovanova, Colin Groves, Antonio Guerreschi, Wolfgang Haak, Tom Higham, Emilia Hofman-Kamińska, Alexander Immel, Marie-Anne Julien, Johannes Krause, Oleksandra Krotova, Frauke Langbein, Greger Larson, Adam Rohrlach, Amelie Scheu, Robert D Schnabel, Jeremy F Taylor, Małgorzata Tokarska, Gilles Tosello, Johannes van der Plicht, Ayla van Loenen, Jean-Denis Vigne, Oliver Wooley, Ludovic Orlando, Rafał Kowalczyk, Beth Shapiro, Alan Cooper
The two living species of bison (European and American) are among the few terrestrial megafauna to have survived the late Pleistocene extinctions. Despite the extensive bovid fossil record in Eurasia, the evolutionary history of the European bison (or wisent, Bison bonasus) before the Holocene (<11.7 thousand years ago (kya)) remains a mystery. We use complete ancient mitochondrial genomes and genome-wide nuclear DNA surveys to reveal that the wisent is the product of hybridization between the extinct steppe bison (Bison priscus) and ancestors of modern cattle (aurochs, Bos primigenius) before 120 kya, and contains up to 10% aurochs genomic ancestry...
October 18, 2016: Nature Communications
https://www.readbyqxmd.com/read/27742770/inhibition-of-demethylase-kdm6b-sensitizes-diffuse-large-b-cell-lymphoma-to-chemotherapeutic-drugs
#20
Rohit Mathur, Lalit Sehgal, Ondrej Havranek, Stefan Köhrer, Tamer Khashab, Neeraj Jain, Jan A Burger, Sattva S Neelapu, R Eric Davis, Felipe Samaniego
Histone methylation and demethylation regulate B-cell development, and their deregulation correlates with tumor chemoresistance in diffuse large B-cell lymphoma, limiting cure rates. Since histone methylation status correlates with disease aggressiveness and relapse, we investigated the therapeutic potential of inhibiting histone 3 Lys27 demethylase KDM6B, in vitro, using the small molecule inhibitor GSK-J4. KDM6B is overexpressed in the germinal center B-cell subtype of diffuse large B-cell lymphoma, and higher KDM6B levels are associated with worse survival in patients with diffuse large B-cell lymphoma treated with R-CHOP...
February 2017: Haematologica
keyword
keyword
30230
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"